Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Voya Investment Management LLC

Voya Investment Management LLC lessened its position in Evolus, Inc. (NASDAQ:EOLS) by 8.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,846 shares of the company’s stock after selling 1,500 shares during the period. Voya Investment Management LLC’s holdings in Evolus were worth $186,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of EOLS. JPMorgan Chase & Co. increased its stake in Evolus by 63.5% in the third quarter. JPMorgan Chase & Co. now owns 169,926 shares of the company’s stock valued at $2,753,000 after purchasing an additional 65,972 shares during the last quarter. KBC Group NV acquired a new position in Evolus in the fourth quarter valued at $49,000. China Universal Asset Management Co. Ltd. increased its stake in Evolus by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company’s stock valued at $148,000 after purchasing an additional 1,291 shares during the last quarter. Rhumbline Advisers increased its stake in Evolus by 2.2% in the fourth quarter. Rhumbline Advisers now owns 80,149 shares of the company’s stock valued at $885,000 after purchasing an additional 1,762 shares during the last quarter. Finally, Principal Financial Group Inc. increased its stake in Evolus by 9.8% in the fourth quarter. Principal Financial Group Inc. now owns 33,370 shares of the company’s stock valued at $368,000 after purchasing an additional 2,989 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on EOLS shares. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Evolus in a research report on Thursday, May 8th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of Evolus in a research report on Thursday, April 10th. Barclays upped their price target on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Finally, BTIG Research began coverage on Evolus in a research note on Thursday, April 17th. They set a “buy” rating and a $21.00 price target for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $23.75.

Evolus Price Performance

EOLS stock opened at $10.13 on Wednesday. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. Evolus, Inc. has a 1 year low of $8.67 and a 1 year high of $17.82. The firm has a market cap of $653.14 million, a P/E ratio of -11.13 and a beta of 1.11. The stock has a 50-day simple moving average of $11.51 and a 200-day simple moving average of $12.47.

Insider Activity

In other Evolus news, insider David Moatazedi sold 6,251 shares of the firm’s stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40. Following the completion of the sale, the insider now owns 508,619 shares in the company, valued at $6,306,875.60. This trade represents a 1.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $60,147.36. Following the sale, the chief marketing officer now owns 95,671 shares of the company’s stock, valued at approximately $1,268,597.46. This trade represents a 4.53% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 60,575 shares of company stock worth $794,369. 5.90% of the stock is currently owned by corporate insiders.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.